DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. | Dexcom said Smart Basal is the ...
Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...
Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...
StockStory.org on MSN
3 Reasons We’re Fans of DexCom (DXCM)
What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...
Carrot announced that it partnered with Oura and Dexcom to deliver actionable, personalized insights supporting fertility ...
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.
In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership with Dexcom, the global leader in glucose biosensing. As part of the ...
A breakthrough live-cell sensor makes DNA repair visible as it happens, unlocking new possibilities in biology and medicine.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 18, 2025 / As we observe National Diabetes Month, St. Joseph Medical is ...
DexCom (DXCM) announced the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback